Roche's Avastin won a new indication in ovarian cancer in Europe. The European Medicines Agency approved the drug for use in patients with newly diagnosed, advanced ovarian cancer, in combination with chemotherapy. Report
Roche's Avastin won a new indication in ovarian cancer in Europe. The European Medicines Agency approved the drug for use in patients with newly diagnosed, advanced ovarian cancer, in combination with chemotherapy. Report